Solar Urticaria
Solar urticaria (SU) is an uncommon but very acute and potentially severe form of physical urticaria. It is marked by the sudden appearance of wheals and erythema with intense itching within just 1–10 minutes of exposure to sunlight or an artificial light source.
In terms of mechanism, SU is quite different from the T-cell–mediated, delayed type IV hypersensitivity seen in PMLE or CAD: it is an immediate type I hypersensitivity reaction mediated by specific IgE antibodies.
- The Pre-Chromophore (Photoallergen) Theory:
- The skin or serum of people with SU contains an endogenous, non-allergenic precursor called a pre-chromophore.
- When it absorbs photons of specific wavelengths (the action spectrum), its three-dimensional structure changes and it becomes a photoallergen (a light-activated autoantigen).
- This photoallergen cross-links specific IgE antibodies already bound to FcεRI receptors on mast cells and basophils, triggering massive degranulation within minutes.
- Inflammatory Mediators:
- Histamine: The main driver of vasodilation and increased permeability of superficial vessels, which produces the wheals, and it stimulates sensory nerve endings to cause fierce itching and burning.
- Tryptase, PGD2 and leukotrienes: Sustain the inflammation and can enter the systemic circulation, causing an anaphylactoid reaction.
- Histopathology:
- Epidermis: Normal, with no spongiosis or keratinocyte necrosis.
- Dermis: Widespread papillary dermal edema with dilated small vessels and a sparse perivascular infiltrate of lymphocytes, neutrophils and eosinophils. Mast cell degranulation is clearly visible on toluidine blue staining. There is no evidence of vasculitis.
Solar urticaria counts as a photoallergic emergency because the reaction develops so quickly and, when a large area of skin is exposed, can progress to solar anaphylaxis. At Haute-Derma, we combine phototesting to pin down the action spectrum with rush photodesensitization and anti-IgE monoclonal antibody therapy (omalizumab), the best options for SU that does not respond to H1 antihistamines.
Clinical Features and Action Spectrum Classification
Symptoms flare very quickly once the patient steps into the sun or is exposed to high-output lighting.
How an Attack Unfolds
- Warning sensations: Prickling, burning or intense itching begins only 1–3 minutes after sun exposure.
- Wheal appearance: Bright red patches appear and quickly rise into sharply defined wheals that are pink or pale in the center.
- Rapid spontaneous resolution: Once the patient moves into the shade or away from the light source, the wheals and itch clear completely within 1–2 hours, leaving no dark marks (PIH) or scarring.
- Systemic symptoms (anaphylactoid reaction): When wheals cover a large area (> 30% BSA), the histamine released into the bloodstream can cause:
- Dizziness, low blood pressure and fainting (syncope).
- Bronchospasm, shortness of breath and wheezing.
- Nausea and severe headache.
Classification by Action Spectrum
- Type I: Triggered by UVB (280–320 nm).
- Type II: Triggered by UVA (320–400 nm); the most common type.
- Type III: Triggered by visible light (400–500 nm).
- Types IV and V: Triggered by UVA plus visible light, or by the entire solar spectrum.
How Solar Urticaria Differs From Other Light-Sensitive Conditions
| Solar Urticaria (SU) | Polymorphous Light Eruption (PMLE) | Cholinergic / Physical Urticaria |
|---|---|---|
| Within 1–10 MINUTES of sun exposure | 24–48 hours after sun exposure | 5–10 minutes after exercise or heat |
| Swollen wheals | Red papules, small vesicles | Tiny 1–3 mm wheals with a red flare |
| Lasts 1–2 HOURS after moving into shade | Lasts 7–14 days | Lasts 30–60 minutes after cooling down |
| Immediate type I hypersensitivity (IgE) | Delayed type IV hypersensitivity (T cells) | Cholinergic nerve stimulation |
| Risk of histamine-driven shock: YES | Risk of histamine-driven shock: none | Risk of histamine-driven shock: very rare |
Diagnosis, Desensitization and Treatment at Haute-Derma
At Haute-Derma, patients with SU are managed with a protocol built around the minimal urticarial dose (MUD) and biologic antibody therapy (Haute-Derma SU Protocol):
Phototesting to Find the Minimal Urticarial Dose (MUD)
- Procedure: Small test squares on the back are exposed to individual wavebands (UVB, UVA1, UVA2, visible light) using a solar simulator.
- Measuring the MUD (minimal urticarial dose): The lowest radiation dose that produces a fully formed wheal after 10 minutes. The MUD lets our doctors gauge severity and track progress during treatment.
High-Dose Second-Generation H1 Antihistamines
- Unlike ordinary hives, solar urticaria usually needs second-generation H1 antihistamines at 2–4 times the standard recommended dose:
- Fexofenadine: 180 mg, 2–4 tablets a day (up to 720 mg/day).
- Bilastine: 20 mg, 2–4 tablets a day (taken on an empty stomach).
- Levocetirizine: 5 mg, 2–4 tablets a day.
Rapid Light Desensitization (Rush Photodesensitization / Rush Hardening)
- How it works: Repeated light doses just below the MUD are given many times over 1–3 days. This prompts mast cells to release their histamine stores gradually until the granules are fully depleted (mast cell depletion).
- Result: The patient reaches a state of temporary tolerance and can go out in the sun without breaking out in hives.
- Maintenance: Patients must get 15–30 minutes of everyday sun exposure each day to keep histamine depleted. After more than 3–4 days indoors, mast cells rebuild their histamine stores and the condition flares again.
Biologic Therapy With Omalizumab (Xolair)
- Indication: Solar urticaria that does not respond to high-dose antihistamines, or patients who cannot undergo light desensitization.
- How it works: Omalizumab is an anti-IgE monoclonal antibody that binds free IgE in the blood and prevents it from attaching to FcεRI receptors on mast cells.
- Dose: 300 mg by subcutaneous injection every 4 weeks. In many treatment-resistant patients it brings symptoms under control, sometimes after only 1–2 injections.
